- Open Access
Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease
© The Author(s). 2018
- Received: 26 June 2018
- Accepted: 30 June 2018
- Published: 20 July 2018
Frontotemporal lobar degeneration (FTLD) is heterogeneous in clinical presentation, neuropathological characteristics and genetics. An expanded GGGGCC hexanucleotide repeat in C9ORF72 is the most common genetic cause of both FTLD and motor neuron disease (MND). Dipeptide repeat polymers (DPR) are generated through repeat-associated non-ATG translation, and they aggregate in neuronal inclusions with a distribution distinct from that of TDP-43 pathology. Recent studies from animal and cell culture models suggest that DPR might be toxic, but that toxicity may differ for specific DPR. Arginine containing DPR (poly-GR and poly-PR) have the greatest toxicity and are less frequent than other DPR (poly-GP, poly-GA). A unique feature of arginine-containing DPR is their potential for post-translational modification by methyl-transferases, which produces methylarginine DPR. In this report, we explored the relationship of DPR and methylarginine to markers of neurodegeneration using quantitative digital microscopic methods in 40 patients with C9ORF72 mutations and one of three different clinicopathologic phenotypes, FTLD, FTLD-MND or MND. We find that density and distribution of poly-GR inclusions are different from poly-GA and poly-GP inclusions. We also demonstrate colocalization of poly-GR with asymmetrical dimethylarginine (aDMA) immunoreactivity in regions with neurodegeneration. Differences in aDMA were also noted by clinical phenotype. FTLD-MND had the highest burden of poly-GR pathology compared to FTLD and MND, while FTLD-MND had higher burden of aDMA than FTLD. The results suggest that poly-GR pathology is associated with toxicity and neurodegeneration. It remains to be determined if dimethylarginine modification of poly-GR could contribute to its toxicity.
- Dipeptide repeat polymers (DPR)
Frontotemporal lobar degeneration (FTLD) is heterogeneous in clinical presentation, neuropathological characteristics and underlying genetic causes. Clinically, FTLD manifests in changes in behavior, personality and language, but it can also be associated with motor neuron disease (MND), including amyotrophic lateral sclerosis (upper and lower motor neurons affected), progressive muscular atrophy (lower motor neurons predominantly affected) and primary lateral sclerosis (upper motor neurons primarily affected) [8, 12, 13]. Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 gene (C9ORF72) are the most common genetic cause of FTLD and MND [7, 24], which are collectively referred to as c9FTLD-MND. The neuropathological features of c9FTLD-MND include nuclear RNA foci, inclusions composed of repeat-associated non-ATG (RAN) translated dipeptide repeat polymers (DPR) and TDP-43 pathology. Of these features, DPR pathology and nuclear RNA foci are unique and highly specific to c9FTLD-MND. RAN translation can occur in both sense and antisense directions generating five different DPR: poly-(glycine-alanine/poly-GA), poly-(glycine-arginine/poly-GR) and poly-(glycine-proline/poly-GP) encoded by the sense strand, and poly-(proline-alanine/poly-PA), poly-(proline-arginine/poly-PR) and poly-(proline-glycine/poly-PG) by the antisense strand [1, 11, 21]. In human brains, DPR inclusions are detected predominantly in neurons as cytoplasmic inclusions, but nuclear inclusions and rare inclusions in glial cells are also found . There is evidence that DPR inclusions are detected in presymptomatic individuals before significant neurodegeneration and TDP-43 pathology is detected [19, 32]. Recent progress in developing animal models of c9FTLD-MND suggests that toxicity of specific DPR polymers is variable. Several pathogenic mechanisms, not mutually exclusive, may be at play including nuclear dysfunction, altered RNA splicing, impaired nucleocytoplasmic transport, altered RNA granule dynamics, and disruption of proteostasis. Of the various DPR species, poly-PR and poly-GR are most toxic in Drosophila  and in cell culture models [9, 15, 30, 31, 33, 34]. The reasons that poly-PR and poly-GR are more toxic remain unknown, but given their high arginine content, one might hypothesize that methylarginine post-translational modification might contribute to their toxicity. Arginine residues in polypeptides can be modified by methyltransferases to conjugate one (monomethylarginine) or two (dimethylarginine) methyl groups. Dimethylarginine modifications have been reported in proteins in human plasma and urine, and their levels are increased in conditions associated with enhanced protein breakdown, such as tumor growth and neurodegenerative disorders . There are two isomers of dimethylarginine, symmetric dimethylarginine (sDMA) and asymmetric dimethylarginine (aDMA). The biologic function of DMA is not well known; however, elevated levels of aDMA in plasma predict poor prognosis in many diseases, such as cerebrovascular disease and Crohn’s disease, where DMA modification is considered toxic . The presence of DMA modifications has not been specifically studied in c9FTLD-MND.
Several studies have reported clinicopathological correlates of DPR in brains of c9FTLD-MND, but most have been relatively small autopsy series and used mostly semiquantitative methods [6, 17, 26]. It remains to be determined if there are correlations of specific DPR with clinical or neuropathological subtypes of C9ORF72-related disease. To address this issue, we sought evidence to support our hypothesis that arginine-containing DPR, poly-GR in particular, might correlate with the severity of neuropathology and that DMA modification might be related to a gain of toxicity in poly-GR. To investigate this, we systematically evaluated sense strand DPR (poly-GA, poly-GP and poly-GR), as well as aDMA in 40 patients with FTLD, FTLD-MND or MND. We found that poly-GR pathology correlated with neurodegeneration and clinicopathologic subtype. Further, we detected a correlation between the distribution of poly-GR and aDMA pathologies. Taken together, our results suggest a possible mechanism of poly-GR toxicity that could be the basis of novel therapeutic approaches.
Forty cases of FTLD or MND with C9ORF72 repeat expansion mutation were obtained from the Mayo Clinic brain bank. The C9ORF72 expansion carriers had pathological diagnoses of FTLD, MND or FTLD-MND. All cases were submitted to or autopsied by the brain bank for neurodegenerative disorders at the Mayo Clinic in Jacksonville, Florida. Clinical information (age at death, sex, clinical diagnosis, disease duration, and family history) was obtained from available medical records. The left hemibrain was fixed in 10% formalin, and the right hemibrain was frozen at − 80 °C. Formalin-fixed tissue was sampled with standardized dissection methods and embedded in paraffin blocks.
All cases had hexanucleotide repeat expansions in C9ORF72 based on a repeat-primed polymerase chain reaction method that detects expansions of the GGGGCC hexanucleotide, and for most cases, the expansions was confirmed with Southern blotting. 
Gross and macroscopic neuropathological assessment was performed by standardized procedures. Formalin-fixed, paraffin-embedded tissue samples were cut at 5 μm thickness and mounted on glass slides for further study. The neuropathologic assessment included immunohistochemistry for phospho-TDP-43 (pTDP-43; mouse monoclonal; Cosmo Bio USA, Carlsbad, CA) and C9RANT antibody . A TDP-43 pathologic subtype was assigned to each case using the harmonized classification scheme  based upon morphology and distribution of lesions in cortical and subcortical regions .
Immunohistochemistry and double-label immunofluorescence
Immunohistochemistry was performed on 5-μm thick sections from formalin-fixed paraffin embedded tissue. Glass-mounted sections were de-parafinized in xylene and rehydrated in ethanol and dH2O. Rabbit polyclonal antibodies used for DPR immunohistochemistry were as follows: poly-GA (Rb9880), poly-GP (Rb5823), poly-GR (Rb7810) (Leonard Petrucelli, Mayo Clinic, Jacksonville, FL [1, 11]). A rabbit polyclonal antibody (ASYM24 07–414, MilliporeSigma, Burlington, MA) was used for immunohistochemistry for aDMA. Regions of interest were middle frontal gyrus (FCtx), motor cortex (MCtx) and hippocampus. Adjacent sections were immunostained for phospho-TDP-43 as above. All Immunoperoxidase sections were processed on a DAKO AutostainerPlus (Agilent/DAKO, Santa Clara, CA) with the DAKO EnVisionTM+ system-HRP with diaminobenzidine as the chromogen. Nonspecific antibody binding was blocked with normal goat serum (Sigma, St Louis, MO).
For double immunofluorescence staining, a rat monoclonal antibody was used to detect poly-GR (5H9, MilliporeSigma, Burlington, MA) and a rabbit polyclonal antibody was used to detect aDMA (MilliporeSigma, Burlington, MA). The fluorochromes were Alexa Fluor 568 and Alexa Fluor 488 conjugated to anti-rabbit or anti-rat IgG (Invitrogen/ThermoFisher, Waltham, MA).
Assessment of neurodegeneration
For assessment of neurodegeneration, H&E stained sections of FCtx, MCtx and hippocampus were evaluated. Degeneration was graded semiquantitatively as absent (0), mild (1), moderate (2) or severe (3) based on the presence of spongiosis, neuronal loss and gliosis. In FCtx, neurodegeneration was typically associated with superficial laminar spongiosis, while in the hippocampal dentate fascia, discontinuity in the density of granular neurons was used as an indicator of neuronal loss and neurodegeneration. In hippocampal subfields – CA4 and CA2/3 – degeneration was assessed by neuronal loss and astrogliosis (see Additional file 1: Figure S1).
Digital microscopy methods used in this study have been described previously . Briefly, immunostained glass slides were scanned on an Aperio ScanScope XT slide scanner (Aperio Technologies/Leica Biosystems, Buffalo Grove, IL) producing high resolution digital images. The regions of interest in the hippocampus included the entire hippocampus, as well as delimited subregions of dentate fascia, CA4 sector and CA2/3 sector. In MCtx and FCtx, the region of interest was the entire thickness of the cortex where the pial surface was parallel to the cortical gray-white junction. Digital image analysis was performed using Aperio ImageScope software. A color deconvolution algorithm was used to count the number of pixels that were strongly immunostained by the chromogen. The output variable was percentage of strong positive staining relative to total pixels in the region of interest.
Analytic algorithms for poly-GA had to be adapted to exclude signals two standard deviations above and below the mean because some cases had unexplained background staining. Given this limitation, we also used manual counting methods for poly-GA, as well as for aDMA. In all cases, aDMA labeled not only cytoplasmic inclusions, but also many nuclei presumably due to detection of methylated histones or other nuclear proteins . The poly-GA and aDMA manual counts were performed on digital images. In order to make comparisons between the various DPR, it was also necessary to perform manual counts for poly-GP and poly-GR. The number of inclusions detected from manual counts was assessed in the same area traced for image analysis. Manual counts and positive pixel burden from color deconvolution image analysis were highly correlated for both poly-GP and poly-GR (Additional file 2: Figure S2). Only the motor cortex had poor correlation between poly-GP manual counts and positive pixel burden, in part due to prominent cytoplasmic immunoreactivity in large neurons, including Betz cells. These did not represent inclusions in that they had diffuse cytoplasmic staining, instead of compact cytoplasmic inclusion bodies, which were manually counted. As with image analysis, manual counts were expressed as density per square millimeter by dividing the manual count by total area of the annotated region of interest.
Cell culture experiments
HEK-293 T cells were grown in Opti-Mem plus 10% FBS and 1% penicillin-streptomycin. To examine methylation of poly-GR proteins, HEK-293 T cells were grown in 12-well plates or on coverslips in 24-well plates. Cultures were transfected with 1 μg (12-well plates) or 0.5 μg (24-well plates) of an expression vector[GFP, GFP-(GR)50 or GFP-(GR)100 using Lipofectamine 2000 (Life Technology). Four hours after transfection, the cultured cells were treated with methylarginine transferase inhibitor, AdOx (A7154, Sigma), at concentration of 5 or 20 μM. DMSO was used as vehicle control. Twenty-four hours after treatment, the cultured cells were harvested for Western blot analysis or fixed for immunofluorescence staining.
HEK-293 T cells were fixed with 4% paraformaldehyde in PBS for 15 min, and then permeabilized with PBS-0.5% Triton X-100 for 10 min. To examine aDMA, cells were blocked with 5% nonfat milk for 1 h at room temperature, and then incubated overnight at 4 °C with rabbit polyclonal anti-aDMA antibody (ASYM24, Millipore). After washing, cells were incubated with the corresponding Alexa Fluor 568-conjugated goat anti-rabbit secondary antibody (1:500, Molecular Probes) at room temperature for 2 h. After washing, they were mounted with Vectashield Mounting Media with DAPI (Vector Laboratories). Images were obtained on a Zeiss LSM 510 META confocal microscope. To quantify the number of cells positive for GFP and aDMA, microscopic fields were randomly selected at 40X magnification. For each field, the number of GFP-positive cells and aDMA-positive aggregates, as well as aggregates with double staining, were manually counted, blinded to condition. These counts were used to calculate the average percentage of aDMA aggregates in cells expressing GFP, GFP-(GR)50 or GFP-(GR)100.
Biochemical studies of cell lysates
Cell pellets were lysed in co-immunoprecipitation (co-IP) buffer (50 mM Tris–HCl, pH 7.4, 300 mM NaCl, 1% Triton X-100, 5 mM EDTA) plus 2% SDS, and both protease and phosphatase inhibitors, sonicated on ice, and then centrifuged at 16,000×g for 20 min. Supernatants were saved as cell lysates. The protein concentration of supernatants was determined by BCA assay (Thermo Scientific) prior to Western blot analysis. Cell lysates were diluted with 2 × SDS-loading buffer at a 1:1 ratio (v/v), and then heated at 95 °C for 5 min. Equal amounts of protein were loaded into 12-well 4–20% Tris-glycine gels (Novex). After transferring proteins to membranes, membranes were blocked with 5% nonfat dry milk in TBS plus 0.1% Tween 20 (TBST) for 1 h, and then incubated with rabbit polyclonal anti-GFP antibody (A-6455, 1:4000, Life Technologies), rabbit polyclonal anti-GR antibody (Rb7810, 1:2000), rabbit polyclonal anti-aDMA antibody (07–414, 1:1000, EMD Millipore), or mouse monoclonal or GAPDH antibody (H86504M, 1:10000, Meridian Life Science) overnight at 4 °C. Membranes were washed in TBST and incubated with donkey anti-rabbit or anti-mouse IgG antibodies conjugated to horseradish peroxidase (1:5000; Jackson ImmunoResearch) for 1 h. Protein expression was visualized by enhanced chemiluminescence treatment and exposure to film.
Sigma Plot Version 12 (Systat Software, San Jose, CA) was used for statistical analyses. Due to small sample sizes, non-parametric Kruskal-Wallis analysis of variance on ranks (ANOVA on Ranks) was performed on quantitative measures to assess differences between the groups. Post hoc pairwise comparisons were performed between each of the groups using Mann-Whitney rank sum test. For categorical data (e.g., sex and APOE genotype), a Chi-square test was used to compare groups. Fisher’s exact test was used for comparison of pairwise categorical data if the counts were less than 5. Correlative analysis was performed using Spearman rank order correlation. A p-value < 0.05 was considered statistically significant.
Demographics features of study cohort
Demographics of clinicopathologic subgroups
Age at death
74 (71, 83)*
6.4 (4.4, 10)*
61 (60, 68)*
3.6 (2.2, 5.5)
56 (50, 68)
2.4 (1.3, 3.5)
Spectrum of poly-GA, poly-GP and poly-GR pathology
Poly-GR inclusion distribution among clinicopathologic subgroups
To evaluate whether poly-GA, poly-GP or poly-GR pathology differs among different clinicopathologic subgroups, we quantified lesion burden with image analysis. Although there were no significant differences between the subgroups for burden of poly-GA and poly-GP, poly-GR was significantly different in the three clinicopathologic subgroups. While overall lesions were sparse, we found greater burden of poly-GR inclusions in the FCtx of FTLD-MND compared to MND, and significantly more poly-GR inclusions in specific hippocampal subfields (i.e. CA2/3) of FTLD-MND compared to FTLD, as well as a trend for increases in CA4 of FTLD-MND compared to FTLD (Additional file 3: Table S1). We found poly-GR density was significantly different in FTD/MND in frontal cortex and hippocampus.
Correlations between poly-GR pathology and neurodegeneration
Correlations of phospho-TDP-43 and DPR burden with neurodegeneration
r = − 0.19
r = 0.20
r = 0.10
p = 0.28
p = 0.24
p = 0.57
r = − 0.14
r = 0.26
r = 0.31
p = 0.42
p = 0.12
p = 0.06
r = 0.45
r = 0.33
r = − 0.01
p = 0.004
p = 0.04
p = 0.96
r = 0.46
r = 0.40
r = 0.61
p = 0.004
p = 0.013
p = 0.00006
Spectrum and distribution of poly-GR pathology and aDMA distribution
To assess our hypothesis that DMA modification may contribute to a possible toxic gain of function in poly-GR inclusions, we studied the morphology and distribution of inclusions immunoreactive for aDMA. We also quantified aDMA using western blot analysis in a subset of cases included in the larger immunohistochemical study. Blots were also probed with antibody to sDMA. The focus of this sub-analysis was on four FTLD-MND patients that had the most significant poly-GR pathology. Four FTLD-MND patients without C9ORF72 mutations were included for comparison. We detected high molecular weight aDMA-immunoreactive species in brain lysates of c9FTLD-MND (Additional file 5: Figure S4), but not of sporadic FTLD-MND. We did not detect any differences between c9FTLD-MND and sporadic FTLD-MND for sDMA (Additional file 5: Figure S4).
Given these results, we focused only on aDMA in subsequent histopathologic studies. We characterized the spectrum of poly-GR and aDMA pathology in C9ORF72 patients. As mentioned above, poly-GR neuronal inclusions were observed throughout the brain. Only a few glial inclusions and isolated neuronal intranuclear inclusions were detected, while no dystrophic neurites were detected (Fig. 1). Immunohistochemistry for aDMA labeled neuronal inclusions as well as many nuclei, the latter probably related to physiologic methylation of nuclear proteins such as histones (Fig. 1). As we observed for poly-GR, most of the inclusions immunoreactive for aDMA were neuronal cytoplasmic inclusions; glial inclusions were sparse, and no dystrophic neurites were found.
Similar distribution of poly-GR and aDMA immunoreactivities in c9FTLD-MND brains
Clinicopathological correlations of poly-GR and aDMA pathology based on manual inclusion counts
Burden of DPR and aDMA by region in clinicopathologic subgroups
6.4 (3.8, 9.4)
310 (110, 470)
6 (4.1, 9.5)
5.6 (4.5, 8.3)
5.8 (3.7, 12)
7.5 (5.6, 15)
420 (320, 630)
9.5 (6.6, 13)
9.7 (4.7, 15)
14 (6.2, 17)
7.4 (5.8, 13)
380 (280, 480)
10 (7.4, 14)
8.2 (3.0, 12)
9.3 (6.5, 13)
120 (71, 262)
8 (6.7, 13)
19 (13, 33)
10 (6.7, 13)
13 (11, 18)
180 (98, 270)
13 (7.4, 18)
31 (19, 39)
10 (8.0, 14)
10 (6.6, 16)
130 (86, 230)
13 (10, 17)
27 (16, 39)
11 (4.9, 18)
3.0 (2.2, 4.2)
16 (9.5, 48)
3.0 (2.3, 5.6)
5.1 (3.3, 9.3)
2.6 (1.3, 5.5)
6.8 (3.7, 9.5)*
49 (26, 86)*
8.5 (6.8, 12)*
17 (11, 26)*
4.7 (3.1, 7.9)
26 (18, 51)
7.5 (4.7, 8.8)
12 (3.7, 22)
2.6 (1.2, 4.9)
3.3 (2.8, 4.7)
83 (31, 100)
10 (6.8, 14)
16 (10, 37)
3.4 (2.1, 5.6)
5.5 (3.1, 8.2)
77 (21, 140)
17 (14, 22)*
25 (17, 36)
5.6 (4.6, 6.8)
4.0 (2.1, 7.4)
53 (31, 81)
15 (12, 20)
15 (6, 29)
In vitro evidence of poly-GR methylation
An expanded hexanucleotide repeat in C9ORF72 is the most frequent cause of FTLD and MND. One consequence of the expanded repeats is formation of DPR polymers through unconventional RAN translation [1, 21]. Despite increasing evidence from animal and cell culture models suggesting individual DPR have different degrees of toxicity, the manifestations of this toxicity and pathomechanisms are poorly understood in the human brain. Moreover, the relationship of DPR-related neuropathology with various clinicopathologic subtypes of C9ORF72-related disease is not well understood. In this study, we focused on poly-GR and provide evidence that density of poly-GR inclusions correlates with neurodegeneration more robustly than other DPR, especially in individuals with the most severe clinicopathologic phenotype, FTLD-MND. In addition, we explored a possible association of poly-GR toxicity with post-translational modification by methylation. In clinicopathological analysis, we demonstrated differences in distribution of poly-GR inclusions compared with poly-GA and found that certain brain regions, such as the hippocampal DF, have abundant poly-GA inclusions, but very few poly-GR inclusions. Moreover, poly-GR inclusions are closely associated with histologic features of neurodegeneration, especially in the hippocampus and FCtx. We found a similar distribution of poly-GR and aDMA-positive inclusions, and co-localization of poly-GR with aDMA. Of the three clinicopathologic phenotypes of C9ORF72-related disease, the FTLD-MND subgroup had the most inclusions immunoreactive for poly-GR and aDMA, especially in the FCtx and in several subregions of the hippocampus.
Only a few studies have addressed possible differences in DPR species in clinicopathological subtypes of C9ORF72-related disease. A semiquantitative neuropathologic study by Mackenzie and coworkers of 8 cases of FTLD, 16 of FTLD-MND and 11 of MND, found no relationship between specific DPR species and clinicopathologic phenotype, except for moderate association of poly-GA-positive dystrophic neurites with histologic markers of degeneration in the frontal cortex . In another semiquantitative study by Schludi and coworkers in a cohort of 3 FTLD, 4 FTLD-MND and 2 MND, poly-PR inclusions were more abundant in FTLD than MND in the hippocampus, while poly-GA inclusions were more abundant in cerebellar granular layer of FTLD than both FTLD-MND and MND cases, but neither poly-PR nor poly-GA correlated with neurodegeneration . In contrast, we found correlations between poly-GR and neurodegeneration in a larger series of cases using quantitative digital microscopic methods. Another unique finding in our study was that patients with the most severe clinicopathologic phenotype, namely those with both FTLD and MND, had higher lesion burden that the other two clinicopathologic groups. Like Schludi and coworkers , we found the highest density of poly-GR in FTLD-MND. On the other hand, we were not able to detect any difference between FTD and MND. The FTD group had the oldest age at death and longest disease duration; therefore, greater neurodegeneration might be associated with clearance of poly-GR pathology. While the three largest neuropathologic studies of DPR pathology in C9ORF72-related disease and a range of clinicopathologic subtypes, different quantitative methods and different antibodies for immunohistochemistry, there were several notable similarities. All found that poly-GR inclusions were less abundant than poly-GA (and poly-GP) inclusions and that certain brain regions had propensity for DPR inclusions, such as specific hippocampal subregions (DF, CA4 and CA2/3) and the cerebellar internal granular cell layer. The current study is the first to use digital pathology and quantitative methods, including color deconvolution image analysis, to objectively assess the burden of DPR pathology and histologic markers of neurodegeneration.
A recent study by Saberi and coworkers suggested poly-GR inclusions co-localize with TDP-43 in dendritic structures in a small series (n = 5) of MND compared with sporadic ALS (n = 3) . These findings differ from our results and those of others [17, 26], who find little evidence for poly-GR immunoreactive dystrophic neurites.
Various pathomechanisms have been proposed for C9ORF72-related disease based on animal and cell culture models, including loss of function of C9ORF72 leading to neuroinflammation , nuclear dysfunction due to alternative RNA splicing, perturbations in RNA metabolism, formation of DNA/RNA hybrids, RNA foci and defects in nucleocytoplasmic transport. The most characteristic pathologic hallmark of C9ORF72-related is widespread and regionally-specific neuronal DPR polymer inclusions and RNA foci. Given that two of the DPR contain arginine polymers, we hypothesized that post-translational modification of these DPR by methylarginine transferases might uniquely contribute to their greater toxicity. We found evidence to support methylation of poly-GR, while poly-PR was not amenable to study due to the paucity of these inclusions and the lack of reliable and sensitive reagents for their detection. Double immunostaining methods showed colocalization of aDMA immunoreactivity in poly-GR inclusions (Fig. 3). In contrast, there was very little colocalization of poly-GA and aDMA in neuronal inclusions (data not shown). Moreover, the distribution of poly-GR was highly correlated with the distribution of aDMA (Additional file 6: Table S2). We found that aDMA immunoreactivity was present in normal nuclei of various cell types, which is assumed to be physiologic methylation of nuclear proteins, such as histones and RNA-binding proteins . Boeynaems and coworkers previously reported nuclear signal of aDMA in dentate fascia neurons of healthy controls . We also detected nuclear aDMA in control cases (Additional file 7: Figure S5). Therefore, it is reasonable the aDMA nuclear labeling represents physiological methylation. In these proteins, DMA posttranslational modification occurs at sites with a consensus glycine/arginine rich (GAR) motif, which may be mimicked by poly-GR. Recent studies show that in addition to GAR-domain class of proteins, other proteins can be targeted by arginine methyltransferases . Based upon histologic features and morphology, the nuclear aDMA we detected was not only in intranuclear inclusions, but also in other nuclear structures. Unlike normal controls, in c9FTLD-MND aDMA was found in the neuronal cytoplasm and it co-localized with poly-GR, especially in the hippocampus.
Given the strong correlation between poly-GR and aDMA, their association with neurodegeneration, and their relative abundance in patients with the most severe clinicopathologic phenotype (FTLD-MND), we hypothesized that post-translational modification of poly-GR may be a novel mechanism of gain of toxicity of poly-GR. In support of this, poly-GR cytoplasmic inclusions in cultured cells expressing GFP-(GR)100 were frequently co-labeled with a sensitive and specific antibody to aDMA. Treating the cells with an arginine methyltransferase inhibitor (AdOx), which has intrinsic cytotoxic properties, decreased the numbers of poly-GR cytoplasmic inclusions at times and concentrations not associated with significant cytotoxicity. These findings suggest that formation of poly-GR cytoplasmic inclusions might be influenced by aDMA modification.
Although post-translational modification of proteins with aDMA is often toxic in various tissues in human diseases, including the brain [5, 27, 29], the effects of post-translational aDMA modification is not well understood in the brain. Regarding clinical and experimental studies of CNS disease and aDMA, in hepatic encephalopathy, elevated aDMA levels could potentially contribute to cognitive dysfunction through oxidative stress, restriction of cerebral blood flow and inflammation . In ischemic stroke, elevated levels of aDMA might contribute to brain injury through endothelial cell damage, and aDMA also might be involved in nitric oxide associated oxidative stress and excitotoxicity . In neurodegenerative disorders, Suarez-Calved and coworkers reported that mono-methylated arginine is frequent in FTLD-FUS, but not in ALS-FUS. Unmethylated and mono-methylated methylarginine FUS had much higher binding affinities to the nuclear receptor of FUS, transportin-1, compared to aDMA FUS . To complicate matters, DMA modification is also considered to both positively and negatively regulate protein-protein interactions .
A limitation of our study is the inability to detect specific methylated forms (e.g., mono-methylation, symmetrical di-methylation and asymmetrical di-methylation) of poly-GR (and poly-PR). There is also no direct way to know the effect of the DPR polymer repeat length on post-translational modification. Our in vitro cell culture studies used repeat lengths of 50- and 100-mers. These are much smaller repeats that seen in disease brain based upon their mobility on western blots. In this regard, it is interesting to note that Bennion Callister and co-workers pointed out that repeat length effects subcellular distribution of DPR, with smaller repeats producing inclusions in the nucleus (specifically in nucleoli) and larger repeats (> 1000) producing inclusions in the cytoplasm . We were able to detect both nuclear and cytoplasmic inclusions in our cell culture models with much smaller repeats. It remains to be determined if repeat length affects methylation modification. Nevertheless, we suggest that current studies provide preliminary evidence from human neuropathology that post-translational modification of arginine residues may play a role in the toxicity of poly-GR. Clearly, there is need for further study.
In summary, we provide evidence that poly-GR is more closely associated with markers of neurodegeneration than poly-GA and poly-GP. Preliminary evidence suggests that methylation may contribute to this toxicity. Furthermore, in our small clinicopathologic series poly-GR seems to be more abundant in patients with FTLD-MND compared to FTLD or MND. Investigating the contribution of poly-GR to neuronal dysfunction, TDP-43 pathology and neurodegeneration may shed additional light on disease pathogenesis and lead to new therapeutic targets.
We thank the patients and their families who donated brains to help further our knowledge of c9FTLD-MND. We are grateful to Linda Rousseau and Virginia Phillips for histological support; and to Monica Castanedes-Casey for immunohistochemistry support.
This study is supported by NIH: P01 NS084974–04, R01 AG037491–08, P50 AG016574–19.
Availability of data and materials
The data and materials, including digital pathology and glass slides, are available for sharing upon request.
NS, KFB, Y-JZ, KR, TFG, MEM and RR contributed to data acquisition and analysis. LP and DWD provided support and scientific oversight for the studies. All authors contributed in writing the final manuscript. All authors have approved the final version of the manuscript.
Ethics approval and consent to participate
All autopsies were performed after informed consent of the legal-next-of-kin or someone with legal authority to grant permission. The brain bank for neurodegenerative disorders at Mayo Clinic operates under approved guidelines of the Mayo Clinic Institutional Review Board and studies on autopsy samples are considered exempt from human subjects research under 45 CFR 46.101.
Consent for publication
The study is performed as part of research funded by the National Institutes of Health and is intended to be widely available to the public.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW 3rd, Rademakers R, Boylan KB, Dickson DW, Petrucelli L (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77:639–646View ArticlePubMedPubMed CentralGoogle Scholar
- Bennion Callister J, Ryan S, Sim J, Rollinson S, Pickering-Brown SM (2016) Modelling C9orf72 dipeptide repeat proteins of a physiologically relevant size. Hum Mol Genet 25:5069–5082PubMedPubMed CentralGoogle Scholar
- Boeynaems S, Bogaert E, Michiels E, Gijselinck I, Sieben A, Jovicic A, De Baets G, Scheveneels W, Steyaert J, Cuijt I, Verstrepen KJ, Callaerts P, Rousseau F, Schymkowitz J, Cruts M, Van Broeckhoven C, Van Damme P, Gitler AD, Robberecht W, Van Den Bosch L (2016) Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci Rep 6:20877View ArticlePubMedPubMed CentralGoogle Scholar
- Chen S, Li N, Deb-Chatterji M, Dong Q, Kielstein JT, Weissenborn K, Worthmann H (2012) Asymmetric dimethyarginine as marker and mediator in ischemic stroke. Int J Mol Sci 13:15983–16004View ArticlePubMedPubMed CentralGoogle Scholar
- Czarnecka A, Milewski K, Zielinska M (2017) Asymmetric Dimethylarginine and hepatic encephalopathy: cause, effect or association? Neurochem Res 42:750–761View ArticlePubMedGoogle Scholar
- Davidson YS, Barker H, Robinson AC, Thompson JC, Harris J, Troakes C, Smith B, Al-Saraj S, Shaw C, Rollinson S, Masuda-Suzukake M, Hasegawa M, Pickering-Brown S, Snowden JS, Mann DM (2014) Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun 2:70View ArticlePubMedPubMed CentralGoogle Scholar
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245–256View ArticlePubMedPubMed CentralGoogle Scholar
- Dickson DW, Josephs KA, Amador-Ortiz C (2007) TDP-43 in differential diagnosis of motor neuron disorders. Acta Neuropathol 114:71–79View ArticlePubMedGoogle Scholar
- Freibaum BD, Taylor JP (2017) The role of dipeptide repeats in C9ORF72-related ALS-FTD. Front Mol Neurosci 10:35View ArticlePubMedPubMed CentralGoogle Scholar
- Gayatri S, Bedford MT (2014) Readers of histone methylarginine marks. Biochim Biophys Acta 1839:702–710View ArticlePubMedPubMed CentralGoogle Scholar
- Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T, Daughrity L, Dunmore JH, Castanedes-Casey M, Chew J, Cosio DM, van Blitterswijk M, Lee WC, Rademakers R, Boylan KB, Dickson DW, Petrucelli L (2013) Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol 126:829–844View ArticlePubMedPubMed CentralGoogle Scholar
- Geser F, Brandmeir NJ, Kwong LK, Martinez-Lage M, Elman L, McCluskey L, Xie SX, Lee VM, Trojanowski JQ (2008) Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol 65:636–641View ArticlePubMedGoogle Scholar
- Geser F, Stein B, Partain M, Elman LB, McCluskey LF, Xie SX, Van Deerlin VM, Kwong LK, Lee VM, Trojanowski JQ (2011) Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathol 121:509–517View ArticlePubMedPubMed CentralGoogle Scholar
- Josephs KA, Stroh A, Dugger B, Dickson DW (2009) Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol 118:349–358View ArticlePubMedPubMed CentralGoogle Scholar
- Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, Kim J, Yun J, Xie Y, McKnight SL (2014) Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345:1139–1145View ArticlePubMedPubMed CentralGoogle Scholar
- Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K, Weng SM, Haass C, Kretzschmar HA, Edbauer D, Neumann M (2013) Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol 126:859–879View ArticlePubMedGoogle Scholar
- Mackenzie IR, Frick P, Grasser FA, Gendron TF, Petrucelli L, Cashman NR, Edbauer D, Kremmer E, Prudlo J, Troost D, Neumann M (2015) Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol 130:845–861View ArticlePubMedGoogle Scholar
- Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DM, Lee VM (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113View ArticlePubMedPubMed CentralGoogle Scholar
- Mann DM (2015) Dipeptide repeat protein toxicity in frontotemporal lobar degeneration and in motor neurone disease associated with expansions in C9ORF72-a cautionary note. Neurobiol Aging 36:1224–1226View ArticlePubMedGoogle Scholar
- Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IOC, Pietrzyk J, Cleverley K, Nicoll AJ, Pickering-Brown S, Dols J, Cabecinha M, Hendrich O, Fratta P, Fisher EMC, Partridge L, Isaacs AM (2014) C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345:1192–1194View ArticlePubMedPubMed CentralGoogle Scholar
- Mori K, Arzberger T, Grasser FA, Gijselinck I, May S, Rentzsch K, Weng SM, Schludi MH, van der Zee J, Cruts M, Van Broeckhoven C, Kremmer E, Kretzschmar HA, Haass C, Edbauer D (2013) Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol 126:881–893View ArticlePubMedGoogle Scholar
- Murray ME, Przybelski SA, Lesnick TG, Liesinger AM, Spychalla A, Zhang B, Gunter JL, Parisi JE, Boeve BF, Knopman DS, Petersen RC, Jack CR Jr, Dickson DW, Kantarci K (2014) Early Alzheimer's disease neuropathology detected by proton MR spectroscopy. J Neurosci 34:16247–16255View ArticlePubMedPubMed CentralGoogle Scholar
- O'Rourke JG, Bogdanik L, Yanez A, Lall D, Wolf AJ, Muhammad AK, Ho R, Carmona S, Vit JP, Zarrow J, Kim KJ, Bell S, Harms MB, Miller TM, Dangler CA, Underhill DM, Goodridge HS, Lutz CM, Baloh RH (2016) C9orf72 is required for proper macrophage and microglial function in mice. Science 351:1324–1329View ArticlePubMedPubMed CentralGoogle Scholar
- Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Holtta-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chio A, Restagno G, Borghero G, Sabatelli M, Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268View ArticlePubMedPubMed CentralGoogle Scholar
- Saberi S, Stauffer JE, Jiang J, Garcia SD, Taylor AE, Schulte D, Ohkubo T, Schloffman CL, Maldonado M, Baughn M, Rodriguez MJ, Pizzo D, Cleveland D, Ravits J (2017) Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta NeuropatholGoogle Scholar
- Schludi MH, May S, Grasser FA, Rentzsch K, Kremmer E, Kupper C, Klopstock T, Arzberger T, Edbauer D (2015) Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol 130:537–555View ArticlePubMedPubMed CentralGoogle Scholar
- Schwedhelm E, Boger RH (2011) The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 7:275–285View ArticlePubMedGoogle Scholar
- Suarez-Calvet M, Neumann M, Arzberger T, Abou-Ajram C, Funk E, Hartmann H, Edbauer D, Kremmer E, Gobl C, Resch M, Bourgeois B, Madl T, Reber S, Jutzi D, Ruepp MD, Mackenzie IR, Ansorge O, Dormann D, Haass C (2016) Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS. Acta Neuropathol 131:587–604View ArticlePubMedGoogle Scholar
- Tain YL, Hsu CN (2017) Toxic Dimethylarginines: asymmetric Dimethylarginine (ADMA) and symmetric Dimethylarginine (SDMA). Toxins (Basel) 9Google Scholar
- Tao Z, Wang H, Xia Q, Li K, Li K, Jiang X, Xu G, Wang G, Ying Z (2015) Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Hum Mol Genet 24:2426–2441View ArticlePubMedGoogle Scholar
- Todd TW, Petrucelli L (2016) Insights into the pathogenic mechanisms of chromosome 9 open reading frame 72 (C9orf72) repeat expansions. J Neurochem 138(Suppl 1):145–162View ArticlePubMedGoogle Scholar
- Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A, Pribadi M, Phillips JJ, Gaus SE, Hixson JD, Garcia PA, Rabinovici GD, Coppola G, Geschwind DH, Petrucelli L, Miller BL, Seeley WW (2016) Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain 139:3202–3216View ArticlePubMedPubMed CentralGoogle Scholar
- Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB, Pasinelli P, Ichida JK, Trotti D (2014) Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84:1213–1225View ArticlePubMedPubMed CentralGoogle Scholar
- Yang D, Abdallah A, Li Z, Lu Y, Almeida S, Gao FB (2015) FTD/ALS-associated poly(GR) protein impairs the notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. Acta Neuropathol 130:525–535View ArticlePubMedPubMed CentralGoogle Scholar